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Abstract. Yaws is a neglected tropical disease targeted for eradication by 2020. Kiribati, a Paciﬁc Island nation, was
previously endemic for yaws but lacks recent data from which its current endemicity status could be determined. This
study tested antibody responses to Treponema pallidum to determine if transmission of yaws is taking place among
children in Kiribati. Using a commercially available T. pallidum particle agglutination kit (Serodia®,MASTDiagnostics), we
tested dried blood spots, collected during population-based trachoma prevalence surveys on Tarawa Atoll and Kiritimati
Island, for long-lived treponemal antibodies. Dried blood spots from 1,420 children aged 1–9 years were tested. Only two
were positive, suggesting T. pallidum is not being widely transmitted among children in the settings sampled. These data
require support fromadditional surveys to demonstrate the absence of clinical signs of disease andmolecular evidenceof
infection, to conﬁrm that yaws is no longer endemic in Kiribati.
Yaws is a chronic disease that affects the skin, bones, and
cartilage. It is caused by infection with Treponema pallidum
subsp. pertenue. Yaws used to be endemic across the tropics,
before a 1950s WHO/UNICEF campaign used parenteral peni-
cillin to produce a ∼95% reduction in cases globally.1 However,
because of reduced resources and political commitment, pre-
mature discontinuation of the campaign, and a lack of follow-on
surveillance, yaws cases subsequently resurged in many coun-
tries.2 Oral azithromycin has recently been shown to be highly
effective in treating yaws.3 Although potentially compromised by
the emergence of azithromycin resistance in T. pallidum subsp.
pertenue,4 mass drug administration (MDA) with azithromycin is
now the main tool for a renewed WHO-led yaws eradication
drive.5
The Paciﬁc is one of themost heavily yaws-endemic regions,
with roughly 80% of the known global disease burden found in
Papua New Guinea, Solomon Islands, and Vanuatu alone
(Figure 1). Kiribati is a Paciﬁc nation with a total population of
approximately 110,000 people. Like many countries, it was
previously endemic for yaws, but lacks recent data.6 Other
neglected tropical diseases remain endemic in Kiribati and its
yaws endemicity status requires clariﬁcation. Before this study,
azithromycin MDA had not been previously conducted in Kir-
ibati; it was not known whether the prevalence of active
trachoma7,8 should be the onlymetric informing planning on its
deployment.
Serological testing is key to the diagnosis of treponemal in-
fections and the WHO recommends serological surveys to
provide evidence that transmission of yaws has been inter-
rupted.5 Treponema-speciﬁc antibodies, such as those de-
tected by the T. pallidum particle agglutination (TPPA) test,
remain positive for life following infection, and an absence or
very low level of serological reactivity in children is therefore
consistent with interruption of yaws transmission. (Congenital
syphilis could also cause TPPA positivity in children.) Dried
blood spot (DBS) testing has been validated for these assays,9
facilitating sero-surveyswithout venepuncture or transport and
storage of serum.
Aspart of public health–level investigations into trachoma in
the Paciﬁc Islands, we collected DBS samples during two
population-based prevalence surveys conducted in Kiribati in
November 2015 and August 2016. Here, we use those sam-
ples to provide evidence as to whether or not yaws trans-
mission is ongoing.
Each survey was designed to estimate the prevalence of the
active trachoma sign trachomatous inﬂammation—follicular
(TF) in children aged 1–9 years. The Kiritimati survey was
powered to have 95%conﬁdence to detect a TF prevalence of
20% in 1- to 9-year-olds with an absolute precision of 3%.
A total of 221 households were visited; these were selected
using compact segment sampling. The number of households
selected from each villagewas proportional to that village’s
population size.8 The Tarawa surveywas powered to estimate
an expected TF prevalence in 1- to 9-year-olds of 10% with
absolute precision of 3% at the 95% conﬁdence level. Thirty-
six villages were selected from the complete list of villages in
the evaluation unit, using a probability-proportional-to-size
methodology. Within each village, 30 households were drawn
at random from a hat.
In both sites, the clinical examination and sample collection
and handling followed the same methodology, described
elsewhere.8 In Kiritimati, ﬁngerprick blood samples were only
collected from those aged 1–9 years, whereas in Tarawa, all
consenting participants aged ³ 1 year had ﬁngerprick blood
collected.
Dried blood spot samples were tested as previously de-
scribed.9 Brieﬂy, one spot from each selected subject’s card
was eluted to a 1:25 dilution in PBST and tested without tech-
nical replicates, using the DBS-modiﬁed TPPA assay (Serodia,
MAST Diagnostics). Samples were reported as positive, neg-
ative, or indeterminate. All resultswere reviewed and agreed by
two independent researchers (R. H. and M. M.). Indeterminate
results were not retested because of the limited number of
DBSs available for this study. Positive controls from previous
surveys10 and manufacturer’s positive and negative controls
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were included in each run and gave expected results. To de-
termine seroprevalence estimates, 35 indeterminate results
were removed from both the numerator and denominator.
Traditionally, active yaws studies are undertaken in 5 to
14-year-olds because this group harbors the peak prevalence
of primary yaws. However the WHO recommends testing chil-
dren aged 1–5 years when assessing for interruption of trans-
mission. We therefore tested all samples from children aged
1–9 years, covering both the recommended age range for
evaluating transmission interruption and a slightly older age
group, to look for evidence of both current and recent
transmission between children. To harness the full epide-
miological power of the samples, we also tested an arbi-
trary selection of at least 60 samples, collected during the
Tarawa survey, from each of the following age groups:
10–20 years, 21–30 years, 31–40 years, 41–50 years, and
³ 51+ years. As secondary analyses, we calculated the
seroprevalence for children aged 1–5 and 6–9 years (Kir-
itimati and Tarawa) and 10–14 and ³15 years (Tarawa only).
Statistical analysis was conducted in R 3.4.2. Ethical ap-
proval was granted by the London School of Hygiene &
Tropical Medicine (6319, 8355, 10136) and the Kiribati
Ministry of Health and Medical Services (Kiritimati: No-
vember 8, 2015; Tarawa: May 25, 2016). Leaders of each
village provided verbal consent for community entry.
Adults gave written informed consent and parents/
guardians provided written informed consent for children
aged < 18 years.
In total, 1,420 children aged 1–9 years (49.8% male) pro-
vided DBS samples. Only two individuals in this group had a
reactive TPPA test (0.14%; 95% CI: 0.02–0.57%). Both of
these individuals were resident on Kiritimati. The seropreva-
lence in children was 0% (95% CI: 0.00–0.47%) on Tarawa
and 0.50% (95% CI: 0.09–2.01%) on Kiritimati. Seropreva-
lences by age group are shown in Table 1. Overall, these data
suggest it is unlikely that yaws transmission is ongoing in
Kiribati. This conclusion is supported by routine data: no
suspected yaws cases have been reported to the Ministry of
Health over the last 5 years (A. Tonganibeia, Personal Com-
munication), although yaws is no longer a notiﬁable disease. It
is unlikely that any study would demonstrate a complete ab-
sence of apparent seroreactivity to T. pallidum, even in pop-
ulations in which transmission of yaws had truly been
interrupted, because the reported speciﬁcity of TPPA per-
formed on DBSs is 99.0% (95% CI: 98.1–99.5%).9 The prev-
alence of seropositivity in children is therefore consistent with
a complete absence of true positives and the anticipated
number of false positives. Equally, the TPPA assay does not
distinguish between immunological responses to the sub-
species of T. pallidum, so the few reactive results in children
could represent congenital syphilis.
Similarly, TPPA positivity in 4.8%of adults (³ 15 years) might
represent childhood infection with T. pallidum subsp. pertenue
or be a result of exposure to syphilis (for which no national
prevalence data are available). Given the low prevalence of
seropositivity among children, wecontend that seroreactivity in
the lower age divisions of this population was almost certainly
generated by exposure to T. pallidum subsp. pallidum, not
yaws. The TPPA assay has a sensitivity of 95.5% (95% CI:
91.3–98.0%), so it is possible the true seroprevalence was
higher than observed. The relatively high prevalence of sero-
positivity in adults gives us conﬁdence that sample handling
and processing were unlikely to be responsible for the very low
prevalence of reactivity in younger age groups.
Our study has some limitations. First, DBS samples were col-
lectedduring trachomasurveys inwhichaskinexamination11was
not performed, and we therefore lack clinical data on yaws-like
lesions. Second, each survey was designed to estimate a TF
prevalenceof∼10%to20%andwouldhavebeenunderpowered
to detect an extremely low prevalence of seropositivity to
T. pallidum, which might be expected in the peri-elimination
context. However, because of Kiribati’s small population size, the
sample testedwasgreater than1%of all residents of the country.
Third,we had samples fromonly three of the 21 inhabited islands;
although together Tarawa and Kiritimati support 60% of the na-
tional population,12 we cannot rule out the existence of higher
seroprevalence on islands not represented here.
We made use of DBSs to test a proportion of Kiribati’s
population for treponemal antibodies. Dried blood spots are
simple to collect in low-resource settings, easy to store, and
can act as a sample set for future serological or molecular
evaluations. By using samples collected during trachoma sur-
veys, we performed a cost-effective study without further ﬁeld-
work,demonstrating thebeneﬁtsof integratedNTDsurveys,13–18
and in particular, one of several potential synergies between
programmes targeting trachoma and yaws.19 Determining the
yaws status of 84 formerly endemic countries is a priority of the
yawseradicationprogramme20; this studyprovidesoneexample
of how that might be performed.
Our data will form a valuable component of the evidence
required by Kiribati to achieve certiﬁcation of local yaws
elimination. The WHO presently recommends a period of at
TABLE 1
Results of the TPPA results by age group
Age range n %Male TPPA seropositivity, n (%, 95% CI) Survey Rationale
Primary analysis
1–9 1,420 49.8 2 (0.1, 0.02–0.57) Kiritimati and Tarawa Surveillance for interruption of
transmission and age range of peak
transmission
Secondary analysis
1–5 837 52.0 1 (0.1, 0.01–0.77) Kiritimati and Tarawa Surveillance for interruption of
transmission
6–9 583 46.7 1 (0.2, 0.01–1.11) Kiritimati and Tarawa Surveillance for interruption of
transmission and age range of peak
transmission
10–14 151 55.0 0 (0.0, 0.00–3.09) Tarawa Age range of peak transmission
³ 15+ 289 33.6 14 (4.8, 2.78–8.18) Tarawa –
TPPA = Treponema pallidum particle agglutination.
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least 3 years of surveillance plus sero-surveys to demonstrate
yaws elimination in countries where speciﬁc interventions have
been undertaken to interrupt transmission of yaws. WHO rec-
ommendations for surveillance in countries whose current en-
demicity is unknown are pending, but sero-surveys are likely to
play a role. Based on our data, ongoing transmission of yaws in
Kiribati is highly unlikely.
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